# OnCo record her2-cish-pharmdx (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/her2-cish-pharmdx/>
  a schema:MedicalTest ;
  onco:kind "drug" ;
  schema:identifier "her2-cish-pharmdx" ;
  schema:name "HER2 CISH pharmDx Kit"@en ;
  schema:description "Dako's HER2 gene test read with an ordinary microscope, approved in 2011 to help decide on trastuzumab in breast cancer; the FDA records its approval as withdrawn in January 2018."@en ;
  schema:url <https://onco.cc/drugs/her2-cish-pharmdx/> ;
  schema:dateModified "2026-11-19"^^xsd:date ;
  schema:citation <https://api.fda.gov/device/pma.json?search=pma_number:P100024+AND+supplement_number:%22%22>, <https://open.fda.gov/fields/devicepma.yaml>, <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P100024>, <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-fda-authorized-companion-diagnostic-devices-in-vitro-and-imaging-tools> ;
  onco:status "withdrawn" ;
  onco:tag "test" ;
  onco:modality "Chromogenic in situ hybridisation test (HER2 gene status, breast tumour tissue)" ;
  schema:alternateName "HER2 CISH pharmDx" ;
  onco:approval "US 2011: HER2 gene status as an aid in selecting trastuzumab in breast cancer" ;
  onco:related <https://onco.cc/drugs/her2-fish-pharmdx/>, <https://onco.cc/drugs/her2-testing-assays/> ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/> ;
  onco:companies <https://onco.cc/companies/agilent/> ;
  onco:terms <https://onco.cc/terms/her2-positive/>, <https://onco.cc/terms/companion-diagnostic-term/> .
